This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
New Strong Buy Stocks for July 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
by Zacks Equity Research
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
Why Is Exelixis (EXEL) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
by Swarup Gupta
The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
by Zacks Equity Research
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Exelixis (EXEL) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 12.50% and 5.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR Initiates Dosing in Phase II/III Eye Disorder Study
by Zacks Equity Research
ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
by Zacks Equity Research
Exelixis (EXEL) performance has been impressive so far in 2019 on the back of label expansion of Cabometyx.
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Exelixis (EXEL) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Exelixis (EXEL) closed at $24.76 in the latest trading session, marking a +0.2% move from the prior day.
Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
by Zacks Equity Research
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Exelixis (EXEL) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day.
New Strong Sell Stocks for February 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Implied Volatility Surging for Exelixis (EXEL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?